large cell carcinoma

Summary

Summary: A tumor of undifferentiated (anaplastic) cells of large size. It is usually bronchogenic. (From Dorland, 27th ed)

Top Publications

  1. doi Curcumin inhibits human lung large cell carcinoma cancer tumour growth in a murine xenograft model
    Chin Cheng Su
    Division of General Surgery, Buddhist Tzu Chi General Hospital, Tzu Chi University, Hualien 970, Taiwan
    Phytother Res 24:189-92. 2010
  2. ncbi Immunohistochemical neuroendocrine differentiation is an independent prognostic factor in surgically resected large cell carcinoma of the lung
    Masahiko Harada
    Pathology Division, National Cancer Center Research Institute East, 6 5 1 Kashiwanoha, Kashiwa, Chiba 277 8577, Japan
    Lung Cancer 38:177-84. 2002
  3. ncbi Production of granulocyte-macrophage colony-stimulating factor in a patient with metastatic chest wall large cell carcinoma
    M Watanabe
    Department of Surgery, School of Medicine, Keio University, Tokyo, Japan
    Jpn J Clin Oncol 28:559-62. 1998
  4. ncbi Large cell carcinoma of the lung metastatic to the mandibular gingiva
    Takashi Yoshii
    Department of Dentistry, Hyogo Prefectural Staff Health Center, Kobe, Japan
    J Periodontol 73:571-4. 2002
  5. ncbi Large cell carcinoma arising in bronchogenic cyst
    Marko Jakopovic
    University Hospital for Lung Diseass Jordanovac, Zagreb, Croatia
    J Thorac Cardiovasc Surg 130:610-2. 2005
  6. ncbi Large cell neuroendocrine cervical carcinoma: a report of two cases and review of the literature
    T C Krivak
    Division of Gynecologic Oncology, Department of Pathology, Walter Reed Army Medical Center, 6900 Georgia Avenue, Washington, DC, 20307, USA
    Gynecol Oncol 82:187-91. 2001
  7. ncbi EGFR and KRAS mutations as criteria for treatment with tyrosine kinase inhibitors: retro- and prospective observations in non-small-cell lung cancer
    N Van Zandwijk
    Department of Thoracic Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands
    Ann Oncol 18:99-103. 2007
  8. ncbi Significance of EGFR protein expression and gene amplification in non-small cell lung carcinoma
    Sanja Dacic
    Department of Pathology, Division of Anatomic Pathology, University of Pittsburgh Medical Center, Presbyterian University Hospital, Pittsburgh, PA 15213, USA
    Am J Clin Pathol 125:860-5. 2006
  9. doi A Japanese Lung Cancer Registry study: prognosis of 13,010 resected lung cancers
    Hisao Asamura
    Division of Thoracic Surgery, National Cancer Center Hospital, Tokyo, Japan
    J Thorac Oncol 3:46-52. 2008
  10. ncbi Adjuvant chemotherapy for large cell carcinoma with neuroendocrine features
    A Iyoda
    Division of Pathology, Institute of Pulmonary Cancer Research, Chiba University School of Medicine, Chiba, Japan
    Cancer 92:1108-12. 2001

Research Grants

  1. PREOPERATIVE TREATMENT OF LUNG CANCER WITH rhuMab VEGF
    Gregory Otterson; Fiscal Year: 2003
  2. Molecular Mechanisms Regulating Noncanonical NF-kB Signaling
    Shao Cong Sun; Fiscal Year: 2009
  3. Role of Paxillin in Lung Cancer
    Ravi Salgia; Fiscal Year: 2009
  4. Modeling Airway Lung Cancer and the Role of Inflammation
    Francesco DeMayo; Fiscal Year: 2007
  5. Role of Paxillin in Lung Cancer
    Ravi Salgia; Fiscal Year: 2010
  6. Role of Paxillin in Lung Cancer
    Ravi Salgia; Fiscal Year: 2009
  7. Role of IGFBP -3 in mediating p53-induced apoptosis
    Adda Grimberg; Fiscal Year: 2006
  8. Molecular Mechanisms Mediating NF-kB2/p100 Processing
    Shao Cong Sun; Fiscal Year: 2006
  9. International Lung Cancer Consortium: Pooled analysis o*
    Paul Brennan; Fiscal Year: 2006
  10. Notch signaling in brain tumors
    Charles Eberhart; Fiscal Year: 2007

Detail Information

Publications179 found, 100 shown here

  1. doi Curcumin inhibits human lung large cell carcinoma cancer tumour growth in a murine xenograft model
    Chin Cheng Su
    Division of General Surgery, Buddhist Tzu Chi General Hospital, Tzu Chi University, Hualien 970, Taiwan
    Phytother Res 24:189-92. 2010
    ..The findings indicate that curcumin can inhibit tumour growth in a NCI-H460 xenograft animal model in vivo...
  2. ncbi Immunohistochemical neuroendocrine differentiation is an independent prognostic factor in surgically resected large cell carcinoma of the lung
    Masahiko Harada
    Pathology Division, National Cancer Center Research Institute East, 6 5 1 Kashiwanoha, Kashiwa, Chiba 277 8577, Japan
    Lung Cancer 38:177-84. 2002
    The clinical significance of neuroendocrine (NE) differentiation is unclear in large cell carcinoma (LCC) of the lung...
  3. ncbi Production of granulocyte-macrophage colony-stimulating factor in a patient with metastatic chest wall large cell carcinoma
    M Watanabe
    Department of Surgery, School of Medicine, Keio University, Tokyo, Japan
    Jpn J Clin Oncol 28:559-62. 1998
    ..However, he died of respiratory failure due to progressive tumor growth 56 days after admission. Based on these results it appears that autocrine production of GM-CSF is a possible cause of this leukemoid reaction...
  4. ncbi Large cell carcinoma of the lung metastatic to the mandibular gingiva
    Takashi Yoshii
    Department of Dentistry, Hyogo Prefectural Staff Health Center, Kobe, Japan
    J Periodontol 73:571-4. 2002
    ..Although metastases of malignant tumors to the jaws are not unusual, metastases to the gingival soft tissues are relatively rare...
  5. ncbi Large cell carcinoma arising in bronchogenic cyst
    Marko Jakopovic
    University Hospital for Lung Diseass Jordanovac, Zagreb, Croatia
    J Thorac Cardiovasc Surg 130:610-2. 2005
  6. ncbi Large cell neuroendocrine cervical carcinoma: a report of two cases and review of the literature
    T C Krivak
    Division of Gynecologic Oncology, Department of Pathology, Walter Reed Army Medical Center, 6900 Georgia Avenue, Washington, DC, 20307, USA
    Gynecol Oncol 82:187-91. 2001
    ..These tumors appear to mimic the aggressive behavior of small cell neuroendocrine tumors. Metastasis and recurrent disease are common. Due to the low incidence of these tumors, optimal therapy has not been delineated...
  7. ncbi EGFR and KRAS mutations as criteria for treatment with tyrosine kinase inhibitors: retro- and prospective observations in non-small-cell lung cancer
    N Van Zandwijk
    Department of Thoracic Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands
    Ann Oncol 18:99-103. 2007
    ..Exon 19 deletions that are associated with the best responses might be used for first-line treatment selection, while KRAS mutations could play a role in excluding patients from treatment with TKIs...
  8. ncbi Significance of EGFR protein expression and gene amplification in non-small cell lung carcinoma
    Sanja Dacic
    Department of Pathology, Division of Anatomic Pathology, University of Pittsburgh Medical Center, Presbyterian University Hospital, Pittsburgh, PA 15213, USA
    Am J Clin Pathol 125:860-5. 2006
    ..EGFR protein expression was uncoupled from gene amplification in most cases, although good correlation occurred in a subset of SCCs...
  9. doi A Japanese Lung Cancer Registry study: prognosis of 13,010 resected lung cancers
    Hisao Asamura
    Division of Thoracic Surgery, National Cancer Center Hospital, Tokyo, Japan
    J Thorac Oncol 3:46-52. 2008
    ..The validation of tumor, node, metastasis staging system in terms of prognosis is an indispensable part of establishing a better staging system in lung cancer...
  10. ncbi Adjuvant chemotherapy for large cell carcinoma with neuroendocrine features
    A Iyoda
    Division of Pathology, Institute of Pulmonary Cancer Research, Chiba University School of Medicine, Chiba, Japan
    Cancer 92:1108-12. 2001
    In 1999, the World Health Organization categorized large cell neuroendocrine carcinoma, large cell carcinoma with neuroendocrine differentiation, and large cell carcinoma with neuroendocrine morphology as a variant of large cell carcinoma...
  11. ncbi A comparison of trends in the incidence rate of lung cancer by histological type in the Osaka Cancer Registry, Japan and in the Surveillance, Epidemiology and End Results Program, USA
    Itsuro Yoshimi
    Cancer Information and Epidemiology Division, National Cancer Center Research Institute, Tokyo, Japan
    Jpn J Clin Oncol 33:98-104. 2003
    ..For large cell carcinoma, the decreasing trend began earlier in the SEER...
  12. ncbi Lung large cell carcinoma producing granulocyte-colony-stimulating factor
    Sachiko Hasegawa
    Division of General Thoracic Surgery, Fujita Health University School of Medicine, Toyoake, Aichi, Japan
    Ann Thorac Surg 83:308-10. 2007
    ..We experience a case of lung carcinoma producing granulocyte-colony-stimulating factor treated by resection and chemotherapy. He remains well 2 years and 10 months after surgery, with no recurrence of the carcinoma...
  13. pmc Cytotoxic T lymphocytes directed against a tumor-specific mutated antigen display similar HLA tetramer binding but distinct functional avidity and tissue distribution
    Hamid Echchakir
    Laboratoire Cytokines et Immunologie des Tumeurs Humaines, U487 Institut National de la Santé et de la Recherche Médicale, Institut Gustave Roussy, Institut Fédératif de Recherche 54, F 94805 Villejuif, Cedex, France
    Proc Natl Acad Sci U S A 99:9358-63. 2002
    We have previously identified an antigen (Ag) recognized on a human large cell carcinoma of the lung by a tumor-specific cytotoxic T lymphocyte clone derived from autologous tumor infiltrating lymphocytes (TILs)...
  14. ncbi Lung cancer rates convergence in young men and women in the United States: analysis by birth cohort and histologic type
    Ahmedin Jemal
    Epidemiology and Surveillance Research, American Cancer Society, Atlanta, GA 30329 4251, USA
    Int J Cancer 105:101-7. 2003
    ..incidence rates for white men and women converged rapidly for adenocarcinoma, small cell carcinoma, and large cell carcinoma, but less so for squamous cell carcinoma...
  15. ncbi Primary alveolar-type large cell neuroendocrine carcinoma of the breast
    Wen Chiuan Tsai
    Department of Pathology, Tri Service General Hospital and National Defense Medical Center, Taipei, Taiwan
    Breast J 11:487. 2005
  16. ncbi A point mutation in the alpha-actinin-4 gene generates an antigenic peptide recognized by autologous cytolytic T lymphocytes on a human lung carcinoma
    H Echchakir
    Laboratoire Cytokines et Immunologie des Tumeurs Humaines, U487 Institut National de la Santé et de la Recherche Médicale, Institut Gustave Roussy, F 94805 Villejuif, Cedex, France
    Cancer Res 61:4078-83. 2001
    We have identified an antigen recognized on a human large cell carcinoma by an autologous tumor-specific CTL clone that was derived from mononuclear cells infiltrating the primary tumor...
  17. ncbi Biological markers and DNA flow cytometric analysis in radically resected patients with non-small cell lung cancer. A study of the Perugia Multidisciplinary Team for Thoracic Tumors
    Vienna Ludovini
    Medical Oncology, Azienda Ospedaliera, Perugia, Italy
    Tumori 94:398-405. 2008
    ....
  18. ncbi Differential effect of high doses versus low doses of interleukin-12 on the adoptive transfer of human specific cytotoxic T lymphocyte in autologous lung tumors engrafted into severe combined immunodeficiency disease-nonobese diabetic mice: relation with
    C Asselin-Paturel
    Cytokines et Immunologie des Tumeurs Humaines, , Institut Gustave Roussy, Villejuif, France
    Cancer 91:113-22. 2001
    ..authors have established a specific cytotoxic T-cell line (TIL-Heu) from lymphocytes infiltrating a human large cell carcinoma of the lung (LCC)...
  19. ncbi Fluorine-18-alpha-methyltyrosine positron emission tomography for diagnosis and staging of lung cancer: a clinicopathologic study
    Kyoichi Kaira
    Department of Medicine and Molecular Science, Gunma University Graduate School of Medicine, Maebashi, Gunma, Japan
    Clin Cancer Res 13:6369-78. 2007
    ..Tumor uptake of [(18)F]FMT was compared with that of 2-[(18)F]-fluoro-2-deoxy-D-glucose ([(18)F]FDG) and correlated with L-type amino acid transporter 1 (LAT1) expression...
  20. ncbi Phase I study of carboplatin, irinotecan and docetaxel on a divided schedule with recombinant human granulocyte colony stimulating factor support in patients with stage IIIB or IV non-small cell lung cancer
    Akihisa Fujita
    Division of Respiratory Disease, Minami Ichijo Hospital, Sapporo 060 0061, Japan
    Anticancer Drugs 13:505-9. 2002
    ..The response rate and survival data in this phase I study are encouraging. We considered that the pathogenesis of diarrhea involved not only direct cytotoxic damage to the mucosa, but also bacterial overgrowth...
  21. ncbi A statistical study of lung cancer in the annual of pathological autopsy cases in Japan, from 1958 to 1997, with reference to time trends of lung cancer in the world
    Toyohiko Morita
    Department of Pathology, International Medical Center of Japan, Shinjuku ku, Tokyo 162 8655, Japan
    Jpn J Cancer Res 93:15-23. 2002
    ..The possibility of one group changing to resemble another and of groups converging in the near future is suggested...
  22. ncbi Clinical characterization of pulmonary large cell neuroendocrine carcinoma and large cell carcinoma with neuroendocrine morphology
    A Iyoda
    Division of Pathology, Institute of Pulmonary Cancer Research, Chiba University School of Medicine, Chiba, Japan
    Cancer 91:1992-2000. 2001
    b>Large cell carcinoma has been classified as four potential types based on its neuroendocrine morphology and evidence of neuroendocrine differentiation discernible by immunohistochemistry or electron microscopy...
  23. ncbi Changes in the distribution of lung cancer cell types and patient demography in a developing multiracial Asian country: experience of a university teaching hospital
    Chong Kin Liam
    Division of Respiratory Medicine, Department of Medicine, University of Malaya Medical Centre, Faculty of Medicine, 50603 Kuala Lumpur, Malaysia
    Lung Cancer 53:23-30. 2006
    ..2% from 25.2% while that of large cell carcinoma had decreased to 3.3% from 11.9%...
  24. ncbi [Expression and clinical significance of apoptosis-related oncogenes in stage I-II non-small cell lung cancer]
    Dao Feng Wang
    State Key Laboratory of Oncology in South China, Guangzhou, Guangdong 510060, P R China
    Ai Zheng 25:359-62. 2006
    ..This study was to investigate the expression and prognostic significance of representative apoptosis-related oncogenes (Survivin, Bcl-2, Bax, and Fas) in stage I-II NSCLC...
  25. ncbi Infiltrating immune cells, but not tumour cells, express FasL in non-small cell lung cancer: No association with prognosis identified in 3-year follow-up
    Deirdre Toomey
    Department of Surgery, The Royal College of Surgeons in Ireland, Education and Research Centre, Beaumont Hospital, Dublin, Ireland
    Int J Cancer 103:408-12. 2003
    ..We report that lung tumours do not express the FasL, and that although some immune cells are FasL positive, this is not a reflection of general immune cell activation...
  26. ncbi Sex-specific survival advantage with parathyroid hormone-related protein in non-small cell lung carcinoma patients
    Randolph H Hastings
    Research, Anesthesiology, and Medicine Services, VA San Diego Healthcare System, VA Mediucal Center, 3350 La Jolla Village Drive, San Diego, CA 92161, USA
    Clin Cancer Res 12:499-506. 2006
    ..However, its relationship with survival has not been evaluated in a large-scale investigation...
  27. ncbi Heterogeneity of stage IIIA non-small cell lung cancers (NSCLC) and evaluation of late results of surgical treatment
    J Gawrychowski
    Department of Thoracic Surgery, Poland
    Eur J Surg Oncol 29:178-84. 2003
    ..The aim of the study was assessment of the heterogeneity of stage IIIA non-small cell lung cancers (NSCLC) and the late results of surgical treatment...
  28. ncbi Pleural lavage cytology before and after lung resection in non-small cell lung cancer patients
    Sotarou Enatsu
    Department of Thoracic Oncology, National Cancer Center Hospital East, Kashiwa, Japan
    Ann Thorac Surg 81:298-304. 2006
    ....
  29. ncbi Concurrent two-dimensional radiotherapy and weekly docetaxel in the treatment of stage III non-small cell lung cancer: a good local response but no good survival due to radiation pneumonitis
    Hiroshi Onishi
    Department of Radiation Oncology, Yamanashi Medical University, 1110 Shimokato Tamaho Cho, Nakakoma gun, Yamanashi 409 3898, Japan
    Lung Cancer 40:79-84. 2003
    ....
  30. ncbi Prognostic models in patients with non-small-cell lung cancer using artificial neural networks in comparison with logistic regression
    Taizo Hanai
    Department of Biotechnology, Graduate School of Engineering, Nagoya University, Chikusa ku, Nagoya 469 8603, Japan
    Cancer Sci 94:473-7. 2003
    ....
  31. ncbi Predictive value of expression of P53, Bcl-2 and lung resistance-related protein for response to chemotherapy in non-small cell lung cancers
    Toshiyuki Harada
    First Department of Medicine, Hokkaido University School of Medicine, Kita ku, Sapporo 060 8638, Japan
    Cancer Sci 94:394-9. 2003
    ..These findings indicate that immunostaining for P53 and LRP using TBB specimens may be useful for dividing patients with NSCLC into chemoresponsive and chemoresistant groups...
  32. ncbi P63 expression in lung carcinoma: a tissue microarray study of 408 cases
    N H C Au
    Genetic Pathology Evaluation Centre, Department of Pathology and Prostate Research Centre, Vancouver General Hospital, The British Columbia Cancer Agency, Vancouver, British Columbia, Canada
    Appl Immunohistochem Mol Morphol 12:240-7. 2004
    ..These results suggest that p63 may be involved in oncogenesis in a broader range of tumors than was previously thought...
  33. ncbi Carbonic anhydrase IX in early-stage non-small cell lung cancer
    Seok Jin Kim
    Department of Medicine, Thoracic Oncology Program, Duke University Medical Center and Durham Veterans Affairs Hospital, Durham, North Carolina, USA
    Clin Cancer Res 10:7925-33. 2004
    ..We hypothesized that CA IX expression is related to tumor cell proliferation and poor disease-free survival in patients with early-stage non-small-cell lung cancer (NSCLC)...
  34. ncbi ADAM8 as a novel serological and histochemical marker for lung cancer
    Nobuhisa Ishikawa
    Laboratory of Molecular Medicine, Human Genome Center, Institute of Medical Science, The University of Tokyo, Tokyo, Japan
    Clin Cancer Res 10:8363-70. 2004
    ..Purpose and..
  35. ncbi Neuroendocrine differentiation in non-small cell lung cancer and its relation to prognosis and therapy
    M C Howe
    Department of Histopathology, South Manchester University Hospital, Manchester, UK
    Histopathology 46:195-201. 2005
    ..The conclusions of previous studies have been inconsistent. This paper aims to provide an answer by examining a large series together with a comprehensive critique of the literature...
  36. pmc Detection of oncogenic virus genomes and gene products in lung carcinoma
    L Brouchet
    Department of Respiratory Diseases, CHU Rangueil Larrey, 31059 Toulouse Cedex, France
    Br J Cancer 92:743-6. 2005
    ..Taken together, our data strongly suggest that the conventional human oncogenic viruses (HPV, EBV, HCMV, HHV-8 and SV40) are unlikely to play some role in the development of lung carcinomas....
  37. ncbi Results of surgical intervention for p-stage IIIA (N2) non-small cell lung cancer: acceptable prognosis predicted by complete resection in patients with single N2 disease with primary tumor in the upper lobe
    Masayoshi Inoue
    Department of Thoracic Surgery, Toneyama National Hospital, Toyonaka City, Osaka, Japan
    J Thorac Cardiovasc Surg 127:1100-6. 2004
    ..The objective of this study was to identify the subpopulation of patients with N2 disease who can benefit from surgical intervention...
  38. ncbi Comparison between segmentectomy and larger resection of stage IA non-small cell lung carcinoma
    A Campione
    Department of Thoracic and Cardiovascular Surgery, University Hospital Le Scotte, Siena, Italy
    J Cardiovasc Surg (Torino) 45:67-70. 2004
    ..The frequency of recurrence and new primary cancer varies from one report to another while the role of sublobar resection is still debated...
  39. ncbi Tissue inhibitor of metalloproteinase 1 is an independent predictor of prognosis in patients with nonsmall cell lung carcinoma who undergo resection with curative intent
    Valerie Gouyer
    Unité INSERM 560, Place de Verdun, Lille, France
    Cancer 103:1676-84. 2005
    ..In this study, mRNA expression levels of MMP-1, MMP-9, TIMP-1, and TIMP-2 were evaluated in patients with resected NSCLC, and their associations with disease progression and prognosis were determined...
  40. ncbi Border between N1 and N2 stations in lung carcinoma: lessons from lymph node metastatic patterns of lower lobe tumors
    Morihito Okada
    Department of Thoracic Surgery, Hyogo Medical Center for Adults, Akashi City, Japan
    J Thorac Cardiovasc Surg 129:825-30. 2005
    ..We examined the spread pattern of lymph node metastases, investigated the prognosis according to the level of the involved nodes, and conclusively analyzed the border between N1 and N2 stations...
  41. ncbi Distribution according to histologic type and outcome by gender and age group in Taiwanese patients with lung carcinoma
    Kuan Yu Chen
    Division of Pulmonary Medicine, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan
    Cancer 103:2566-74. 2005
    ..The objective of the current study was to assess the trend in the evolution of the histologic types in Taiwan and to compare the outcomes of patients with lung carcinoma between different gender and age groups...
  42. ncbi Lung cancer histopathology in the Thrace region of Turkey and comparison with national data
    Celal Karlikaya
    Department of Chest Diseases, Faculty of Medicine, Trakya University, Edirne, Turkey
    Tuberk Toraks 53:132-8. 2005
    ..Monitoring the LC trend in our region can give clues on evolving cigarette design and smoking attitudes and geographic factors...
  43. pmc First-line gemcitabine with cisplatin or epirubicin in advanced non-small-cell lung cancer: a phase III trial
    F M Wachters
    Department of Pulmonary Diseases, University Hospital Groningen, PO Box 30 001, 9700 RB Groningen, The Netherlands
    Br J Cancer 89:1192-9. 2003
    ..Global QOL was not different in both arms. Progression-free survival, overall survival, response rate, and QOL were not different between both arms; however, overall toxicity was more severe in the EG arm...
  44. ncbi Long-term survival and prognostic factors of five-year survivors with complete resection of non-small cell lung carcinoma
    Morihito Okada
    Department of Thoracic Surgery, Hyogo Medical Center for Adults, Kitaohji cho 13 70, Akashi City 673 5885, Hyogo, Japan
    J Thorac Cardiovasc Surg 126:558-62. 2003
    ..We analyzed the long-term follow-up data on cancer-related death in 5-year survivors of complete resection of their non-small cell lung cancer and examined the prognostic factors having an impact on subsequent survival...
  45. ncbi Non-small-cell lung cancer: reirradiation for loco-regional relapse previously treated with radiation therapy
    Takuhito Tada
    Department of Radiology, Osaka City University Graduate School of Medicine, 1 4 3 Asahimachi, Osaka 545 8585, Japan
    Int J Clin Oncol 10:247-50. 2005
    ..We evaluated the efficacy and toxicity of reirradiation for patients with loco-regional relapse of non-small-cell lung cancer after radiation therapy...
  46. ncbi Prognostic factors for the survival of surgically treated patients for non-small cell lung cancer
    Oswaldo J C B Fernandes
    Department of Cardiothoracic Surgery, Orebro University Hospital, Orebro, Sweden
    Acta Oncol 42:338-41. 2003
    ..It is concluded that the best surgical results were observed in women who were operated on at an early stage of disease. A complete resection also contributed to a better outcome, even for patients in stage IIIA and N2 disease...
  47. ncbi Characteristics and prognosis of patients after resection of nonsmall cell lung carcinoma measuring 2 cm or less in greatest dimension
    Morihito Okada
    Department of Thoracic Surgery, Hyogo Medical Center for Adults, Akashi City, Hyogo, Japan
    Cancer 98:535-41. 2003
    ..Therefore, in the current study, the authors analyzed the clinical characteristics of patients who underwent complete resection of these lung tumors, the follow-up data, and the significant prognostic factors...
  48. ncbi Overexpression of Ang-2 mRNA in non-small cell lung cancer: association with angiogenesis and poor prognosis
    Iwao Takanami
    Department of Surgery, Teikyo University School of Medicine, Tokyo 173, Japan
    Oncol Rep 12:849-53. 2004
    ..0028). These data indicate that Ang-2 may contribute to tumor angiogenesis and progression and that Ang-2 gene expression can serve as a useful prognostic marker in NSCLC...
  49. pmc Integrated classification of lung tumors and cell lines by expression profiling
    Carl Virtanen
    Chugai Pharmaceuticals, 3 41 8 Takada, Toshima ku, Tokyo 171 8545, Japan
    Proc Natl Acad Sci U S A 99:12357-62. 2002
    ....
  50. ncbi [Cohort KBP-2000-CPHG: Evaluation of factors influencing survival in lung cancer]
    F Blanchon
    Service de Pneumologie, Hôpital de Meaux, France
    Rev Mal Respir 23:165-71. 2006
    ..Lung cancer continues to have a poor prognosis despite some therapeutic advances...
  51. ncbi Combination of interventional pulmonology techniques (Nd:YAG laser resection and brachytherapy) with external beam radiotherapy in the treatment of lung cancer patients with Karnofsky Index < or =50
    V Canak
    Institute for Pulmonary Diseases of Vojvodina, Sremska Kamenica, Clinic for Pulmonary Oncology, Department for Interventional Pulmonology, Medical Faculty, University of Novi Sad, Serbia
    J BUON 11:447-56. 2006
    ..To compare Nd: YAG laser resection with Nd: YAG laser plus brachytherapy and external beam radiotherapy (EBRT) in the palliation of malignant central airway obstruction symptoms due to lung cancer...
  52. ncbi Comparison of human lung cancer/SCID mouse tumor xenografts and cell culture growth with patient clinical outcomes
    T M Anderson
    Division of Thoracic Surgery, Roswell Park Cancer Institute, A 249 Carlton Building, Buffalo, NY 14263, USA
    J Cancer Res Clin Oncol 129:565-8. 2003
    ..The ability to propagate tumors in vitro appears to be more dependent upon the histological type of tumor and its degree of differentiation...
  53. ncbi Prognostic implications of cell cycle-related proteins in primary resectable pathologic N2 nonsmall cell lung cancer
    Sherif Mohamed
    Department of Thoracic Surgery Graduate School of Medicine Chiba University, Chiba, Japan
    Cancer 109:2506-14. 2007
    ..For the current study, to select an appropriate therapeutic strategy for each patient, patients with N2 NSCLC were stratified into homogenous subgroups according to the expression profiles of cell cycle-related markers...
  54. ncbi Prognostic factors for survival of stage I nonsmall cell lung cancer patients : a population-based analysis of 19,702 stage I patients in the California Cancer Registry from 1989 to 2003
    S H Ignatius Ou
    Division of Hematology Oncology, Department of Medicine, Chao Family Comprehensive Cancer Center, Orange, California 92868, USA
    Cancer 110:1532-41. 2007
    ....
  55. ncbi Early response to platinum-based first-line chemotherapy in non-small cell lung cancer may predict survival
    Bhawna Sirohi
    Lung Unit, Royal Marsden NHS Foundation Trust, Surrey, United Kingdom
    J Thorac Oncol 2:735-40. 2007
    ..We examined radiographic response after two courses of platinum-based induction chemotherapy to see whether this is an early predictor of outcome...
  56. ncbi Can serum markers be used to predict acute and late toxicity in patients with lung cancer? Analysis of RTOG 91-03
    William F Hartsell
    Lutheran General Cancer Center, Park Ridge, IL, USA
    Am J Clin Oncol 30:368-76. 2007
    ....
  57. ncbi Carbon ion radiotherapy for stage I non-small cell lung cancer using a regimen of four fractions during 1 week
    Tadaaki Miyamoto
    Research Center Hospital for Charged Particle Therapy, National Institute of Radiological Sciences, Chiba, Japan
    J Thorac Oncol 2:916-26. 2007
    ..On the basis on the results, a phase II study using a regimen of four fractions during 1 week was performed. The purpose of the present study was to determine the local control and 5-year survival rates...
  58. ncbi Surgical treatment for octogenarians with lung cancer: results from a population-based series of 124 patients
    Hes A P Brokx
    Department of Pulmonology, VU University Medical Center, Amsterdam, The Netherlands
    J Thorac Oncol 2:1013-7. 2007
    ..Previous reports on the outcome of surgery for lung cancer in octogenarians were mainly derived from single institutions. In contrast, this study presents results for all hospitals in a region of 3 million inhabitants...
  59. ncbi The 3' UTR IGF2R-A2/B2 variant is associated with increased tumor growth and advanced stages in non-small cell lung cancer
    Athanassios Kotsinas
    Department of Histology and Embryology, Molecular Carcinogenesis Group, School of Medicine, University of Athens, Athens, Greece
    Cancer Lett 259:177-85. 2008
    ..In conclusion, the IGF2R-A2/B2 variant probably provides a selective advantage for NSCLC progression through increased tumor growth...
  60. ncbi Low frequency of p53 and k-ras codon 12 mutations in non-small cell lung carcinoma (NSCLC) tumors and surgical margins
    Ozgur Vatan
    Department of Biology, Science and Art Faculty, Uludag University, Bursa, Turkey
    Tumori 93:473-7. 2007
    ..Molecular methods may be exploited that are sensitive enough to detect small numbers of tumor cells...
  61. pmc Prognostic role of serum cytokeratin 19 fragments in advanced non-small-cell lung cancer: association of marker changes after two chemotherapy cycles with different measures of clinical response and survival
    B Nisman
    Department of Oncology, Hadassah University Hospital, Jerusalem, Israel
    Br J Cancer 98:77-9. 2008
    ..63 (P=0.01), respectively. In advanced NSCLC patients, NP reflects therapeutic efficacy better than traditional OR. CYFRA 21-1 >or=35% decline seems to be a reliable surrogate marker of treatment efficacy in terms of survival...
  62. ncbi Increased expression of matrix metalloproteinase-2 (MMP-2) predicts tumour recurrence and unfavourable outcome in non-small cell lung cancer
    Tero Leinonen
    Institute of Clinical Medicine, Pathology and Forensic Medicine, University of Kuopio and Kuopio University Hospital, Kuopio, Finland
    Histol Histopathol 23:693-700. 2008
    ..017, p=0.001 and p=0.021, p=0.008, respectively). The present study shows the significant prognostic value of MMP-2 in NSCLC suggesting that the use of MMP-2 is valuable in determining the patients with more aggressive disease...
  63. ncbi Adenomatous polyposis coli gene promoter hypermethylation in non-small cell lung cancer is associated with survival
    J Brabender
    Department of Biochemistry and Molecular Biology and Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, California, CA 90033, USA
    Oncogene 20:3528-32. 2001
    ..High APC promoter methylation is significantly associated with inferior survival, showing promise as a biomarker of biologically aggressive disease in NSCLC...
  64. ncbi Five-year lung cancer screening experience: CT appearance, growth rate, location, and histologic features of 61 lung cancers
    Rebecca M Lindell
    Department of Radiology, Mayo Clinic, Charlton 2 290, 200 1st Street SW, Rochester, MN 55905, USA
    Radiology 242:555-62. 2007
    ....
  65. ncbi Sequential chemotherapy in nonsmall-cell lung cancer: cisplatin and gemcitabine followed by docetaxel
    Anna Ceribelli
    Division of Medical Oncology A, Regina Elena Cancer Institute, Rome, Italy
    Cancer 109:727-31. 2007
    ....
  66. pmc Biological and prognostic role of acid cysteine proteinase inhibitor (ACPI, cystatin A) in non-small-cell lung cancer
    T Leinonen
    Institute of Clinical Medicine, Pathology and Forensic Medicine, University of Kuopio and Kuopio University Hospital, Kuopio, Finland
    J Clin Pathol 60:515-9. 2007
    ..Acid cysteine protease inhibitor (ACPI) is an intracellular protein, often linked to neoplastic changes in epithelium and thought to have an inhibitory role in malignant transformation...
  67. ncbi Clinical usefulness of serum telomerase reverse transcriptase (hTERT) mRNA and epidermal growth factor receptor (EGFR) mRNA as a novel tumor marker for lung cancer
    Norimasa Miura
    Department of Pathophysiological and Therapeutic Science, Faculty of Medicine, Tottori University, Nishicho 86, Yonago, Tottori 683 8503, Japan
    Cancer Sci 97:1366-73. 2006
    ..The data suggest that hTERT mRNA, especially when combined with EGFR mRNA, is a novel and excellent biomarker for pulmonary malignancies to diagnose and assess the clinical stage...
  68. ncbi Expression of glutathione S-transferase pi and glutathione synthase correlates with survival in early stage non-small cell carcinomas of the lung
    Timothy C Allen
    The University of Texas Health Center at Tyler, Tyler, TX 75708, USA
    Hum Pathol 38:220-7. 2007
    ..Manipulation of GST-pi and GSH2 may be a potential basis for treatment of some NSCLC...
  69. ncbi Comorbidity and KPS are independent prognostic factors in stage I non-small-cell lung cancer
    Selim Firat
    Department of Radiation Oncology, Medical College of Wisconsin, Milwaukee, WI 53226, USA
    Int J Radiat Oncol Biol Phys 52:1047-57. 2002
    ..To determine the prognostic role of comorbidity in Stage I non-small-cell lung cancer (NSCLC) treated with surgery or radiotherapy (RT)...
  70. ncbi Prognosis of non-surgically treated, clinical stage I lung cancer patients in Japan
    Akira Motohiro
    Department of Surgery, National Minamifukuoka Chest Hospital, 4 39 1, Yakatabaru, Minami Ku, Fukuoka 815, Japan
    Lung Cancer 36:65-9. 2002
    ..However, some of these patients are not candidates for surgery because of several medical problems. We analyzed prognosis of non-surgically treated, clinical stage I lung cancer patients...
  71. ncbi Survival and risk model for stage IB non-small cell lung cancer
    J Padilla
    Servicio de Cirugía Torácica, Hospital Universitario La Fe, Avda de Campanar 21, 46009 Valencia, Spain
    Lung Cancer 36:43-8. 2002
    ....
  72. ncbi Apoptotic tumor-cell death in response to cell proliferation is influenced by p53 status in resected non-small cell lung cancer
    Fumihiro Tanaka
    Department of Thoracic Surgery, Faculty of Medicine, Kyoto University, Shogoin Kawahara cho 53, Sakyo ku 606 8397, Japan
    Lung Cancer 36:27-32. 2002
    ..These results clearly demonstrated that active cell proliferation and reduced apoptotic cell death in response to cell proliferation resulted in the poor postoperative prognosis in tumor with aberrant expression of p53...
  73. ncbi Prognostic relevance of proliferating cell nuclear antigen and p53 expression in non-small cell lung cancer
    D Dworakowska
    Department of Oncology and Radiotherapy, Medical University of Gdansk, 7 Debinki St 80 211, Gdansk, Poland
    Lung Cancer 35:35-41. 2002
    ..These results suggest the lack of prognostic relevance of p53 and PCNA expression in surgically treated NSCLC patients...
  74. ncbi MCM2 is an independent predictor of survival in patients with non-small-cell lung cancer
    N Ramnath
    Lung Cancer Program, Roswell Park Cancer Institute, Buffalo, NY, USA
    J Clin Oncol 19:4259-66. 2001
    ..Whether MCM2 is predictive of response to therapy needs to be studied...
  75. ncbi [Results of surgical treatment for primary lung cancer; time trends of survival and clinicopathologic features]
    T Osaki
    Department of Surgery II, School of Medicine, University of Occupational and Environmental Health, Japan. Yahatanishi-ku, Kitakyushu 807-8555, Japan
    J UOEH 23:277-83. 2001
    ..4 years. The histologic type included 453 adenocarcinoma, 282 squamous cell carcinoma, and 63 large cell carcinoma. The pathologic stage included 203 stage I A, 171 stage I B, 21 stage II A, 117 stage II B, 180 stage III A,..
  76. doi Bronchogenic carcinoma and secondary aspergillosis--common yet unexplored: evaluation of the role of bronchoalveolar lavage-polymerase chain reaction and some nonvalidated serologic methods to establish early diagnosis
    Mohammed Shahid
    Section of Mycology and Molecular Biology, Department of Medical Microbiology, Jawaharlal Nehru Medical College and Hospital, Aligarh Muslim University, Aligarh, Uttar Pradesh, India
    Cancer 113:547-58. 2008
    ..However, the frequency of secondary aspergillosis in bronchogenic carcinoma still has not been defined clearly in the literature...
  77. ncbi [Benefits of cisplatin-based polychemotherapy in non-small cell bronchogenic carcinoma. Kyushu Lung Cancer Chemotherapy Study Group]
    M Ohta
    Dept of Chest Surgery, National Kyushu Cancer Center Hospital
    Gan To Kagaku Ryoho 15:1901-8. 1988
    ..One hundred nineteen patients with adenocarcinoma or large cell carcinoma were randomized to receive cyclophosphamide, adriamycin, cisplatin and mitomycin C (CAPM) or mitomycin C, ..
  78. ncbi [Quantitative analysis of thyroid transcription factor-1 mRNA expressions in primary lung cancer and its metastatic foci]
    Xiao Yan Bai
    Department of Pathology, Southern Medical University, Guangzhou 510515, China
    Nan Fang Yi Ke Da Xue Xue Bao 28:20-5. 2008
    ....
  79. doi Outcome and treatment strategy in female lung cancer: a single institution experience
    S Cicenas
    Institute of Oncology, Vilnius University, Lithuania
    Adv Med Sci 55:273-80. 2010
    ..To assess the survival rate of female lung cancer treated at the Institute of Oncology of the Vilnius University, Lithuania during the period between 1996-2005...
  80. ncbi Dose-response relationship between probability of pathologic tumor control and glucose metabolic rate measured with FDG PET after preoperative chemoradiotherapy in locally advanced non-small-cell lung cancer
    Noah C Choi
    Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, 100 Blossom Street, Boston, MA 02114, USA
    Int J Radiat Oncol Biol Phys 54:1024-35. 2002
    ....
  81. ncbi Diversity in expression and prognostic significance of G1/S cyclins in human primary lung carcinomas
    Yoh Dobashi
    Department of Pathology, Kitasato University School of Medicine, Kanagawa, Japan
    J Pathol 199:208-20. 2003
    ..Conversely, in adenocarcinoma (AC), proliferating cells revealed cyclin E positivity. Cases of large cell carcinoma showed heterogeneous cyclin E staining patterns, unlike those of SCC or AC...
  82. doi Relationship between maximum standardized uptake value (SUVmax) of lung cancer and lymph node metastasis on FDG-PET
    Atsushi Nambu
    Department of Radiology, University of Yamanashi, 1110 Shimokawato, Chuo, Yamanashi 409 3898, Japan
    Ann Nucl Med 23:269-75. 2009
    ..To evaluate the relationship between SUVmax of primary lung cancers on FDG-PET and lymph node metastasis...
  83. ncbi Neurotensin causes tyrosine phosphorylation of focal adhesion kinase in lung cancer cells
    Julius Leyton
    Cell and Cancer Biology Department, Medicine Branch, National Cancer Institute, National Institutes of Health, Bldg KWC, Rm 300, 9610 Medical Center Drive, Rockville, MD 20850, USA
    Eur J Pharmacol 442:179-86. 2002
    ..Neurotensin bound with high affinity to large cell carcinoma cell line NCI-H1299 as did neurotensin-(8-13), but not neurotensin-(1-7) or levocabastine...
  84. doi Antiproliferative effect of Toona sinensis leaf extract on non-small-cell lung cancer
    Chih Jen Yang
    Department of Internal Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan
    Transl Res 155:305-14. 2010
    ..different non-small-cell lung cancer (NSCLC) cell lines: H441 cells (lung adenocarcinoma), H661 cells (lung large cell carcinoma) and H520 cells (lung squamous cell carcinoma)...
  85. ncbi Analysis of c-myc DNA amplification in non-small cell lung carcinoma in comparison with small cell lung carcinoma using polymerase chain reaction
    S Mitani
    Department of Pathology, Kanagawa Prefectural College of Nursing and Medical Technology, Yokohama, Japan
    Clin Exp Med 1:105-11. 2001
    ..5 to more than 20.0 in adenocarcinoma and squamous cell carcinoma, and from 6.0 to 12.0 in large cell carcinoma. That of small cell carcinoma ranged from 1.8 to 12.0...
  86. ncbi The right upper lobe pulmonary resection performed through the transcervical approach
    Marcin Zielinski
    Department of Thoracic Surgery Pulmonary Hospital, Zakopane, Poland
    Eur J Cardiothorac Surg 32:766-9. 2007
    ..Preliminary report: presentation of the new technique of transcervical right upper lobectomy with transcervical extended mediastinal lymphadenectomy (TEMLA) for NSCLC...
  87. ncbi Familial risk of cancer by site and histopathology
    Kari Hemminki
    Department of Biosciences, Karolinska Institute, Huddinge, Sweden
    Int J Cancer 103:105-9. 2003
    ..Also noteworthy were familial risks of hepatocellular carcinoma (2.48), pancreatic adenocarcinoma (1.92), large cell carcinoma and adenocarcinoma of the lung (2.29 and 2.18, respectively) and clear cell carcinoma of the kidney (2.73)...
  88. ncbi Lung carcinoma: diffusion-weighted mr imaging--preliminary evaluation with apparent diffusion coefficient
    Munetaka Matoba
    Department of Radiology, Kanazawa Medical University, Kahoku, Ishikaw, Japan
    Radiology 243:570-7. 2007
    ..Materials and..
  89. ncbi Morphological and molecular aspects of cancerogenesis in the lung
    L Chyczewski
    Department of Clinical Molecular Biology, Medical Academy, Białystok, Poland
    Folia Histochem Cytobiol 39:149-52. 2001
    ..9%) of squamous cell carcinoma, 42 (23.3%) of adenocarcinoma and 32 (17.8%) of large cell carcinoma. P53 protein and PCNA expressions were detected immunohistochemically (using formalin-fixed, paraffin-..
  90. doi Discordant findings in patients with non-small-cell lung cancer: absolutely normal bone scans versus disseminated bone metastases on positron-emission tomography/computed tomography
    Ilknur Ak
    Eskisehir Osmangazi University Medical Faculty, Department of Nuclear Medicine, 26480 Eskisehir, Turkey
    Eur J Cardiothorac Surg 37:792-6. 2010
    ....
  91. ncbi Radical cystectomy for primary neuroendocrine tumors of the bladder: the university of southern california experience
    Marcus L Quek
    Departments of Urology, Keck School of Medicine, University of Southern California, University of Southern California Norris Comprehensive Cancer Center, Los Angeles, California, USA
    J Urol 174:93-6. 2005
    ..We reviewed our experience with treating these tumors with radical cystectomy to evaluate their histopathological characteristics and clinical outcomes...
  92. ncbi Association of moderate alpha-1 antitrypsin deficiency with lung cancer in the Serbian population
    Aleksandra S Topic
    Institute of Medical Biochemistry, Faculty of Pharmacy, Belgrade, Serbia and Montenegro
    Arch Med Res 37:866-70. 2006
    ..investigate the association of alpha-1 antitrypsin deficiency (AATD) with lung cancer in patients with four different histological types of cancer: squamous cell carcinoma, adenocarcinomas, large cell carcinoma and small cell carcinoma.
  93. ncbi Gemcitabine and docetaxel as second-line chemotherapy for patients with nonsmall cell lung carcinoma who fail prior paclitaxel plus platinum-based regimens
    C Kosmas
    Department of Medicine, Medical Oncology Unit, Helena Venizelou Hospital, Athens, Greece
    Cancer 92:2902-10. 2001
    ..In the current Phase II study, the authors evaluated the combination of gemcitabine and docetaxel in patients with recurrent NSCLC...
  94. ncbi Comparison of MET-PET and FDG-PET for differentiation between benign lesions and lung cancer in pneumoconiosis
    Kakuko Kanegae
    Department of Nuclear Medicine, Hokkaido University Graduate School of Medicine, Kita 15, Nishi 7, Sapporo 060 8638, Japan
    Ann Nucl Med 21:331-7. 2007
    ..The aim of this study was to evaluate and compare the ability of C-11-methionine (MET) and F-18 fluoro-deoxy-D-glucose positron emission tomography (FDG-PET) to diagnose lung cancer in patients with pneumoconiosis...
  95. pmc Identification of five candidate lung cancer biomarkers by proteomics analysis of conditioned media of four lung cancer cell lines
    Chris Planque
    Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario M5G1X5, Canada
    Mol Cell Proteomics 8:2746-58. 2009
    ..backgrounds (non-small cell lung cancer: H23 (adenocarcinoma), H520 (squamous cell carcinoma), and H460 (large cell carcinoma); small cell lung cancer: H1688) to identify secreted or membrane-bound proteins that could be useful as ..
  96. ncbi Complete remissions in chemotherapy of lung cancer models induced in mice by asbestos
    William E Smith
    Health Research Institute, Fairleigh Dickinson University, Madison, NJ, USA
    Mt Sinai J Med 72:23-32. 2005
    ..As a single agent, aziridinylbenzoquinone (AZQ) increased life span but gave no CRs. There were CRs of ASB XIII in all of 8 mice after toxic combined therapy with PCNU and AZQ. There were no CRs in 66 control mice bearing ASB XIII...
  97. ncbi hASH1 expression is closely correlated with endocrine phenotype and differentiation extent in pulmonary neuroendocrine tumors
    Shi Xu Jiang
    Department of Pathology, Kitasato University School of Medicine, Sagamihara, Kanagawa, Japan
    Mod Pathol 17:222-9. 2004
    ..Finally, hASH1 expression correlated with a significantly shortened survival in small-cell carcinoma patients (P=0.041)...
  98. pmc Flow cytometric analysis of Hoechst 33342 uptake as an indicator of multi-drug resistance in human lung cancer
    S A Morgan
    Clinical Oncology and Radiotherapeutics Unit, Addenbrooke s Hospital, Cambridge, UK
    Br J Cancer 60:282-7. 1989
    ..A drug resistant large cell carcinoma line showed only a small reduction (10%) in nuclear binding when compared to the parent line, and this ..
  99. ncbi Proliferative activity and micronucleus frequency after radiation of lung cancer cells as assessed by the cytokinesis-block method and their relationship to clinical outcome
    Y Shibamoto
    Department of Oncology, Chest Disease Research Institute, Kyoto University, Japan
    Clin Cancer Res 4:677-82. 1998
    ..9 days for squamous cell carcinoma (n = 13), 27% and 6.5 days for large cell carcinoma (n = 3), and 30% and 7.0 days for small cell carcinoma (n = 4)...
  100. ncbi Large cell neuroendocrine carcinoma of the lung: a comparison with large cell carcinoma with neuroendocrine morphology and small cell carcinoma
    Wei Xia Peng
    Department of Tumor Pathology, Gunma University Graduate School of Medicine, 3 39 22 Showa machi, Maebashi, Gunma 371 8511, Japan
    Lung Cancer 47:225-33. 2005
    ..neuroendocrine differentiation, LCNEC was immunohistochemically and molecular biologically compared with large cell carcinoma with neuroendocrine morphology (LCCNM), which lacked only biological neuroendocrine differentiation among ..
  101. ncbi Topotecan plus ifosfamide in patients with platinum refractory advanced/metastatic non-small cell lung cancer: a phase II trial
    Vito Lorusso
    Department of Medical Oncology, Oncology Institute, Via Amendola 209, 70126 Bari, Italy
    Oncol Rep 14:1547-51. 2005
    ..median age was 63 years (range 43-76); cell types were: squamous carcinoma (n=17), adenocarcinoma (n=16), large cell carcinoma (n=3), broncho-alveolar carcinoma (n=2) and undifferentiated carcinoma (n=4)...

Research Grants84

  1. PREOPERATIVE TREATMENT OF LUNG CANCER WITH rhuMab VEGF
    Gregory Otterson; Fiscal Year: 2003
    ..Careful comparison/analysis of clinical and biologic information gathered in this study will likely enhance our understanding of tumor growth and progression as well as response to therapy. ..
  2. Molecular Mechanisms Regulating Noncanonical NF-kB Signaling
    Shao Cong Sun; Fiscal Year: 2009
    ..The goal of this revision project is to understand the molecular mechanism by which a protein kinase, NIK, regulates inflammatory T-cell production and EAE pathogenesis. ..
  3. Role of Paxillin in Lung Cancer
    Ravi Salgia; Fiscal Year: 2009
    ..In large cell carcinoma, for example, mutational frequency is up to 18%...
  4. Modeling Airway Lung Cancer and the Role of Inflammation
    Francesco DeMayo; Fiscal Year: 2007
    ..These subtypes are adenocarcinoma, squamous cell carcinoma, small cell carcinoma, and large cell carcinoma. Currently, squamous cell carcinoma and adenocarcinoma are the most common type of lung cancer in the ..
  5. Role of Paxillin in Lung Cancer
    Ravi Salgia; Fiscal Year: 2010
    ..In large cell carcinoma, for example, mutational frequency is up to 18%...
  6. Role of Paxillin in Lung Cancer
    Ravi Salgia; Fiscal Year: 2009
    ..In large cell carcinoma, for example, mutational frequency is up to 18%...
  7. Role of IGFBP -3 in mediating p53-induced apoptosis
    Adda Grimberg; Fiscal Year: 2006
    ..These studies also reflect Dr. Grimberg?s long-term career goals of exploring the interrelatedness of endocrine and oncologic molecular biology principles and applying them to clinical problems of dysregulated growth. ..
  8. Molecular Mechanisms Mediating NF-kB2/p100 Processing
    Shao Cong Sun; Fiscal Year: 2006
    ..abstract_text> ..
  9. International Lung Cancer Consortium: Pooled analysis o*
    Paul Brennan; Fiscal Year: 2006
    ..abstract_text> ..
  10. Notch signaling in brain tumors
    Charles Eberhart; Fiscal Year: 2007
    ..Finally, it is not known if persistent activation of Nbtch2 is sufficient to initiate the formation of medulloblastoma. In Aim IV, we will introduce activated Notch2 into cerebellar precursor cells and assess its transforming capacity. ..
  11. Molecular Mechanism of Genistein (Isoflavone) in Prostate Cancer
    Fazlul Sarkar; Fiscal Year: 2007
    ....
  12. Bioimaging in Radiotherapy for Lung Cancer
    Noah Choi; Fiscal Year: 2007
    ..abstract_text> ..
  13. Lung Cancer Prognosis: FLT PET and DNA Hypermethylation
    Hubert Vesselle; Fiscal Year: 2007
    ..This prognostic information will permit individualization and optimization of therapy for the 41,000 early stage NSCLC patients undergoing surgical resection each year in the United States. ..
  14. Signaling Functions of the Tumor Suppressor CYLD
    Shao Cong Sun; Fiscal Year: 2007
    ..2) Examine how CYLD negatively regulates peripheral T-cell activation and whether the CYLD deficiency causes autoimmunity. (3) Investigate the biochemical mechanism and functional significance of CYLD phosphorylation. ..
  15. Novel Targets of Indoles in Prostate Cancer
    Fazlul Sarkar; Fiscal Year: 2007
    ..abstract_text> ..
  16. Targeting Akt/NF-kappa beta for Pancreatic Cancer Therapy
    Fazlul Sarkar; Fiscal Year: 2007
    ..These results will provide mechanistic as well as pre-clinical data in support of our hypotheses and may open new and novel avenues for the treatment of human pancreatic cancer. ..
  17. Molecular Mechanisms Mediating NF-kB2/p100 Processing
    Shao Cong Sun; Fiscal Year: 2007
    ..abstract_text> ..
  18. FoxM1: A molecular target in pancreatic cancer
    Fazlul H Sarkar; Fiscal Year: 2010
    ..We will test our hypothesis by three specific aims using molecular approaches in vitro and by using animal models in vivo (both orthotopic mouse model and transgenic mouse models of PC). ..
  19. Stat3 in EGFR Driven Non-Small Cell Lung Cancer
    Eric B Haura; Fiscal Year: 2010
    ..mutant EGFR proteins, (2) to characterize the role of Stat3 in regulating proliferation and survival of EGFR-dependent NSCLC, and (3) to evaluate the effects of gefitinib on EGFR-Stat3 signaling in vivo in a prospective clinical trial ..
  20. The IKK/Tpl2 axis of TLR signaling
    Shao Cong Sun; Fiscal Year: 2010
    ....
  21. Notch signaling in brain tumors
    CHARLES GEORGE EBERHART; Fiscal Year: 2010
    ..In Aim IV, we will introduce activated Notch2 into cerebellar precursor cells and assess its transforming capacity. ..
  22. Regulation of T-cell function and autoimmune inflammation by deubiquitinase CYLD
    Shao Cong Sun; Fiscal Year: 2010
    ..This knowledge is important for rational design of effective immunological therapies. ..
  23. Multicentric Pooled Analysis of Second Primary Cancer
    Paul Brennan; Fiscal Year: 2004
    ..g., ultraviolet light); (ii) an investigation of rare cancer types (e.g., bone cancer or sarcomas); and (iii) an investigation of second primary cancers which may be increased due to treatment of a first primary cancer (e.g., leukemia). ..
  24. THE BIOLOGY OF LUNG CANCER-- FDG AND FLUOROTHYMIDINE PET
    Hubert Vesselle; Fiscal Year: 2004
    ..By performing a biologic grading of resectable NSCLC with FDG PET, we will predict which patients will have a worse outcome. This information will allow individualized therapy. ..
  25. ALVEOLAR TYPE II CELL GROWTH IN INJURY
    RANDOLPH HASTINGS; Fiscal Year: 2003
    ..The project will evaluate the potential use of PTHrP-related therapeutic interventions that might speed or improve recovery following silica-induced lung injury. ..
  26. ACTIVATION OF IKB KINASE BY HTLV-I TAX
    Shao Cong Sun; Fiscal Year: 2003
    ..abstract_text> ..
  27. NIK KINASE AND T CELL COSTIMULATION
    Shao Cong Sun; Fiscal Year: 2003
    ..It is also expected that novel signaling molecules will have been isolated which function in the T cell co-stimulatory pathway. ..
  28. Lung Cancer Prognosis: FLT PET and DNA Hypermethylation
    Hubert Vesselle; Fiscal Year: 2009
    ..This prognostic information will permit individualization and optimization of therapy for the 41,000 early stage NSCLC patients undergoing surgical resection each year in the United States. ..
  29. CANCER AND LEUKEMIA GROUP B
    Martin Edelman; Fiscal Year: 2002
    ..The grant will also allow for continuation of meritorious pilot protocols and will allow GCC to monitor and collect data which will produce mutual benefit to the GCC and CALGB. ..
  30. PHASE I TRIALS OF ANTICANCER AGENTS
    Martin Edelman; Fiscal Year: 2002
    ....
  31. Molecular Epidemiology of Esophageal Cancer Prognosis
    Geoffrey Liu; Fiscal Year: 2007
    ..Furthermore, the proposed studies address directly a prioritized research area identified by the NCI Stomach and Esophageal Cancers Progress Review Group (Year 2002). ..
  32. FLT PET to Plan the Best Therapy for Lung Cancer
    Hubert Vesselle; Fiscal Year: 2007
    ..At the conclusion of this study, the insight gained in the response of stage III NSCLCs will allow clinicians to plan the best therapy for these patients. ..
  33. Pilot for a Multicenter Case-Control Study of Pancreatic Cancer in a High Risk r*
    Paul Brennan; Fiscal Year: 2007
    ..The results of a full study have the potential to identify important lifestyle and occupational risk factors for pancreatic cancer and inform future prevention efforts against pancreatic cancer. ..